Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Cash (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Change in Cash for 17 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 90.83% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.3 million through Dec 2025, up 62.28% year-over-year, with the annual reading at -$11.3 million for FY2025, 62.28% up from the prior year.
  • Change in Cash hit $2.9 million in Q4 2025 for Integra Lifesciences Holdings, down from $14.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $315.5 million in Q1 2024 to a low of -$376.7 million in Q2 2024.
  • Historically, Change in Cash has averaged -$11.8 million across 5 years, with a median of $873000.0 in 2023.
  • Biggest five-year swings in Change in Cash: plummeted 20739.45% in 2024 and later soared 18165.82% in 2025.
  • Year by year, Change in Cash stood at $43.2 million in 2021, then crashed by 227.9% to -$55.3 million in 2022, then surged by 104.83% to $2.7 million in 2023, then soared by 1069.21% to $31.2 million in 2024, then crashed by 90.83% to $2.9 million in 2025.
  • Business Quant data shows Change in Cash for IART at $2.9 million in Q4 2025, $14.3 million in Q3 2025, and -$21.2 million in Q2 2025.